2024 Q1 Form 10-Q Financial Statement
#000168316824000255 Filed on January 12, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2022 Q4 |
---|---|---|---|
Revenue | $40.64K | $89.44K | $0.00 |
YoY Change | |||
Cost Of Revenue | $6.220K | ||
YoY Change | |||
Gross Profit | $34.42K | ||
YoY Change | |||
Gross Profit Margin | 84.69% | ||
Selling, General & Admin | $133.7K | $148.9K | $283.9K |
YoY Change | -43.77% | -47.54% | -57.65% |
% of Gross Profit | 388.29% | ||
Research & Development | $107.2K | $112.4K | $62.89K |
YoY Change | 769.57% | 78.76% | -85.71% |
% of Gross Profit | 311.45% | ||
Depreciation & Amortization | $32.86K | $39.46K | $43.19K |
YoY Change | -18.64% | -8.62% | -16.66% |
% of Gross Profit | 95.47% | ||
Operating Expenses | $240.9K | $261.3K | $346.8K |
YoY Change | -3.66% | -24.64% | -68.77% |
Operating Profit | -$206.4K | -$171.9K | -$346.8K |
YoY Change | -17.43% | -50.43% | -68.77% |
Interest Expense | -$119.0K | -$6.620K | -$10.88K |
YoY Change | -94.99% | -39.15% | -94.88% |
% of Operating Profit | |||
Other Income/Expense, Net | $4.680K | -$6.623K | -$10.88K |
YoY Change | -77.7% | -39.12% | -94.88% |
Pretax Income | -$325.5K | -$178.5K | -$357.7K |
YoY Change | -87.6% | -50.09% | -72.97% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$325.5K | -$178.5K | -$357.7K |
YoY Change | -87.6% | -50.09% | -72.97% |
Net Earnings / Revenue | -800.84% | -199.61% | |
Basic Earnings Per Share | -$0.01 | $0.00 | -$0.33 |
Diluted Earnings Per Share | -$0.01 | $0.00 | -$0.33 |
COMMON SHARES | |||
Basic Shares Outstanding | 31.11M shares | 28.31M shares | 1.258M shares |
Diluted Shares Outstanding | 30.99M shares | 27.76M shares | 1.258M shares |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2022 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $37.14K | $81.65K | $21.60K |
YoY Change | -22.22% | 278.01% | -97.25% |
Cash & Equivalents | $37.14K | $81.65K | $21.60K |
Short-Term Investments | |||
Other Short-Term Assets | $126.8K | $69.29K | $78.09K |
YoY Change | 107.53% | -11.27% | -56.17% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $163.9K | $150.9K | $99.69K |
YoY Change | 50.61% | 51.41% | -89.67% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $0.00 | $236.5K | $393.6K |
YoY Change | -100.0% | -39.92% | -33.47% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $116.2K | ||
YoY Change | -79.39% | ||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $0.00 | $236.5K | $509.8K |
YoY Change | -100.0% | -53.62% | -55.88% |
TOTAL ASSETS | |||
Total Short-Term Assets | $163.9K | $150.9K | $99.69K |
Total Long-Term Assets | $0.00 | $236.5K | $509.8K |
Total Assets | $163.9K | $387.4K | $609.5K |
YoY Change | -64.52% | -36.44% | -71.25% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $231.4K | $245.7K | $596.9K |
YoY Change | -67.44% | -58.84% | 197.78% |
Accrued Expenses | |||
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $1.293M | $1.314M | $1.763M |
YoY Change | -16.03% | -25.47% | 65.0% |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.522M | $2.482M | $2.584M |
YoY Change | 1.98% | -3.93% | 73.09% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.522M | $2.482M | $2.584M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $2.522M | $2.482M | $2.584M |
YoY Change | 1.98% | -3.93% | 73.09% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$24.76M | -$24.44M | -$20.91M |
YoY Change | 5.24% | 16.89% | |
Common Stock | $3.111K | $2.831K | $124.00 |
YoY Change | 1301.35% | 2183.06% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$2.359M | -$2.095M | -$1.974M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $163.9K | $387.4K | $609.5K |
YoY Change | -64.52% | -36.44% | -71.25% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2022 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$325.5K | -$178.5K | -$357.7K |
YoY Change | -87.6% | -50.09% | -72.97% |
Depreciation, Depletion And Amortization | $32.86K | $39.46K | $43.19K |
YoY Change | -18.64% | -8.62% | -16.66% |
Cash From Operating Activities | -$124.4K | -$71.85K | -$95.92K |
YoY Change | 571.29% | -25.09% | -84.0% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $1.200K | |
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $20.00K | ||
YoY Change | -19.03% | ||
Cash From Investing Activities | $20.00K | -$1.196K | $0.00 |
YoY Change | -19.03% | -100.0% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | $24.99K | $0.00 |
YoY Change | -100.0% | ||
NET CHANGE | |||
Cash From Operating Activities | -124.4K | -$71.85K | -$95.92K |
Cash From Investing Activities | 20.00K | -$1.196K | $0.00 |
Cash From Financing Activities | 0.000 | $24.99K | $0.00 |
Net Change In Cash | -104.4K | -$48.05K | -$95.92K |
YoY Change | -499.2% | -49.9% | -84.02% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$124.4K | -$71.85K | -$95.92K |
Capital Expenditures | $0.00 | $1.200K | |
Free Cash Flow | -$124.4K | -$73.05K | |
YoY Change | 571.29% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q4 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q4 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--08-31 | |
CY2023Q4 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
CY2023Q4 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2023Q4 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001343009 | |
CY2023Q4 | dei |
Document Type
DocumentType
|
10-Q | |
CY2023Q4 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2023Q4 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-11-30 | |
CY2023Q4 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023Q4 | dei |
Entity File Number
EntityFileNumber
|
000-52403 | |
CY2023Q4 | dei |
Entity Registrant Name
EntityRegistrantName
|
CNBX PHARMACEUTICALS INC. | |
CY2023Q4 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
CY2023Q4 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
46-5644005 | |
CY2023Q4 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
#3 Bethesda Metro Center | |
CY2023Q4 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 700 | |
CY2023Q4 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Bethesda | |
CY2023Q4 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | |
CY2023Q4 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20814 | |
CY2023Q4 | dei |
City Area Code
CityAreaCode
|
(877) | |
CY2023Q4 | dei |
Local Phone Number
LocalPhoneNumber
|
424-2429 | |
CY2023Q4 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023Q4 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023Q4 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023Q4 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023Q4 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2017289 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
387402 | usd |
CY2023Q4 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
31111352 | shares |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
81647 | usd |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
129696 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
69289 | usd |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
94612 | usd |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
150936 | usd |
CY2023Q3 | us-gaap |
Assets Current
AssetsCurrent
|
224308 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
236466 | usd |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
274731 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
387402 | usd |
CY2023Q3 | us-gaap |
Assets
Assets
|
499039 | usd |
CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
245712 | usd |
CY2023Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
335915 | usd |
CY2023Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
1314120 | usd |
CY2023Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
1343584 | usd |
CY2023Q4 | CNBX |
Due To Related Party Current
DueToRelatedPartyCurrent
|
922499 | usd |
CY2023Q3 | CNBX |
Due To Related Party Current
DueToRelatedPartyCurrent
|
836829 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2482331 | usd |
CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2516328 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2023Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
900000000 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
900000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
28311352 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
28311352 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22611352 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22611352 | shares |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2831 | usd |
CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
2261 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
22339965 | usd |
CY2023Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
22239652 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-24437725 | usd |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-24259202 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2094929 | usd |
CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
499039 | usd |
CY2023Q4 | us-gaap |
Revenues
Revenues
|
89437 | usd |
CY2022Q4 | us-gaap |
Revenues
Revenues
|
0 | usd |
CY2023Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
112418 | usd |
CY2022Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
62888 | usd |
CY2023Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
148919 | usd |
CY2022Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
283902 | usd |
CY2023Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
261337 | usd |
CY2022Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
346790 | usd |
CY2023Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-171900 | usd |
CY2022Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-346790 | usd |
CY2023Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-6623 | usd |
CY2022Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-10879 | usd |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-178523 | usd |
CY2022Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-357669 | usd |
CY2023Q4 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
0 | usd |
CY2022Q4 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-59870 | usd |
CY2023Q4 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-178523 | usd |
CY2022Q4 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-417539 | usd |
CY2023Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.001 | |
CY2023Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.001 | |
CY2022Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.33 | |
CY2022Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.33 | |
CY2023Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
27760802 | shares |
CY2023Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
27760802 | shares |
CY2022Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1257927 | shares |
CY2022Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1257927 | shares |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2017289 | usd |
CY2023Q4 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
34975 | usd |
CY2023Q4 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
65908 | usd |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-178523 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2094929 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1632311 | usd |
CY2022Q4 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
75557 | usd |
CY2022Q4 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-59870 | usd |
CY2022Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-357669 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1974293 | usd |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-178523 | usd |
CY2022Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-357669 | usd |
CY2023Q4 | us-gaap |
Depreciation
Depreciation
|
39461 | usd |
CY2022Q4 | us-gaap |
Depreciation
Depreciation
|
43185 | usd |
CY2023Q4 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
11451 | usd |
CY2022Q4 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4541 | usd |
CY2023Q4 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
34975 | usd |
CY2022Q4 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
75557 | usd |
CY2023Q4 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-25323 | usd |
CY2022Q4 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-2687 | usd |
CY2023Q4 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-4533 | usd |
CY2022Q4 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
135784 | usd |
CY2023Q4 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-71846 | usd |
CY2022Q4 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-95915 | usd |
CY2023Q4 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
1196 | usd |
CY2022Q4 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
-0 | usd |
CY2023Q4 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1196 | usd |
CY2022Q4 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd |
CY2023Q4 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
24993 | usd |
CY2022Q4 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | usd |
CY2023Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
24993 | usd |
CY2022Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-48049 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-95915 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
129696 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
117515 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
81647 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
21600 | usd |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-178523 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-24437725 | usd |
CY2023Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
112418 | usd |
CY2022Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
62888 | usd |
CY2023Q4 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyHv4zS5S3A2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
900000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
5700000 | shares |
CY2023Q4 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
65908 | usd |
CY2023Q4 | CNBX |
Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
|
6500 | usd |